Abstract
Over the past several decades, despite advances in understanding the biology of AML, the standard therapy for patients with this disease has changed very little with the notable exception of the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) in the therapy of acute promyelocytic leukemia (APL). The combination of cytarabine and an anthracycline continues to be the basis for most induction and consolidation regimens in other types of AML. Older patients with AML, particularly the septa and octogenarians and those with comorbid conditions, are less able to tolerate the traditional cytotoxic chemotherapy and have been treated using less toxic strategies such as the use of hypomethylating agents decitabine and 5-azacytidine.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
